These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 26490311)
21. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Sun Z; Wang Z; Liu X; Wang D Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988 [TBL] [Abstract][Full Text] [Related]
22. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508 [No Abstract] [Full Text] [Related]
23. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113 [TBL] [Abstract][Full Text] [Related]
24. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039 [TBL] [Abstract][Full Text] [Related]
25. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562 [TBL] [Abstract][Full Text] [Related]
26. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease. Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154 [TBL] [Abstract][Full Text] [Related]
27. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma. Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321 [TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437 [TBL] [Abstract][Full Text] [Related]
30. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Beck JT; Ismail A; Tolomeo C Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117 [TBL] [Abstract][Full Text] [Related]
31. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Blachly JS; Baiocchi RA Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567 [TBL] [Abstract][Full Text] [Related]
32. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800 [TBL] [Abstract][Full Text] [Related]
33. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. Sathe A; Nawroth R Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395 [TBL] [Abstract][Full Text] [Related]
34. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Bartalucci N; Guglielmelli P; Vannucchi AM Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217 [TBL] [Abstract][Full Text] [Related]
35. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169 [TBL] [Abstract][Full Text] [Related]
36. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related]
37. Apoptosis of human prostate cancer cells induced by marine actinomycin X2 through the mTOR pathway compounded by MiRNA144. Liu J; Xie S; Wu Y; Xu M; Ao C; Wang W; Zeng Q; Hu W; Li M Anticancer Drugs; 2016 Mar; 27(3):156-63. PubMed ID: 26645890 [TBL] [Abstract][Full Text] [Related]
38. Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. Li Z; Lu L; Zhou Z; Xue W; Wang Y; Jin M; Qiu Y; Sun W; Fu X; Zhang X; Chang Y; Nan F; Yan J; Wang G; Sun Z; Fu X; Li L; Li X; Wang X; Wu J; Zhang L; Zhang M Br J Haematol; 2018 May; 181(3):406-410. PubMed ID: 28294301 [No Abstract] [Full Text] [Related]
39. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors. Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946 [TBL] [Abstract][Full Text] [Related]
40. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Ettl T; Schwarz-Furlan S; Haubner F; Müller S; Zenk J; Gosau M; Reichert TE; Zeitler K Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]